Accordingly, a small-molecule inhibitor DMX-5804, which exhibits high potency and selectivity towards MAP4K4/6/724, was utilized to suppress YAP phosphorylation in MG in vitro and in vivo. Here, MAP4K4 is linked to myasthenia gravis.